GlassScriptPhysician profile
Nicholas Glen Maggio
NPI 1295398808
$4,908.12
in general payments reported to CMS, 2019-2025
37 companies · $739 in 2025
The $739 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,734 · 2023: $1,556 · 2024: $879 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $783.13 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $683.17 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $491.47 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $397.71 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $319.68 | 2022-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $285.25 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.82 | 2022-2024 | Jardiance |
| Amgen INC. | $156.59 | 2022-2024 | Repatha |
| Abbott Laboratories | $140.23 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $126.83 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $110.16 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $102.12 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $89.32 | 2022-2023 | Gvoke Hypopen |
| Almatica Pharma LLC | $85.78 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Kowa Pharmaceuticals America, INC. | $78.24 | 2022-2023 | Seglentis, Livalo |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Maggio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.